AWM
SVA

Aprio Wealth Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Aprio Wealth Management’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-439
Closed -$284K – 640
2025
Q4 		$284K Buy
+439
New +$284K 0.02% 446

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Aprio Wealth Management's SVA Position: Q1 2026 in Review

Aprio Wealth Management sold out of Sinovac Biotech, Ltd (SVA) in Q1 2026, closing a stake of 439 shares — an estimated $284K sold.

Aprio Wealth Management first reported a position in SVA in Q4 2025 and held it in 1 quarter. The position peaked at $284K in Q4 2025. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Aprio Wealth Management reported no remaining Sinovac Biotech, Ltd position as of Q1 2026 after selling out during the quarter.
  • Aprio Wealth Management sold 439 Sinovac Biotech, Ltd shares in Q1 2026, an estimated $284K.
  • Aprio Wealth Management first reported a position in Sinovac Biotech, Ltd in Q4 2025 and held it in 1 quarter.
  • Aprio Wealth Management's Sinovac Biotech, Ltd position peaked at $284K in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Aprio Wealth Management's 13F filing for Q1 2026, filed 11 May 2026.